Alirocumab and plaque volume, calf muscle blood flow, and walking performance in peripheral artery disease: A randomized clinical trial.

Elona Rrapo-Kaso,Adrian I Loffler,Gina R Petroni,Craig H Meyer,McCall Walker, Jennifer R Kay,Joseph M DiMaria,Kathyrn Domanchuk,James C Carr,Mary M McDermott,Christopher M Kramer

Vascular medicine (London, England)（2023）

引用 0|浏览21

暂无评分

摘要

In this exploratory study, the addition of alirocumab therapy to statins did not alter SFA plaque volume, calf perfusion or 6MWD despite significant LDL lowering. Larger studies with longer follow up that include plaque characterization may improve understanding of the effects of intensive LDL-lowering therapy in PAD .

查看译文

关键词

PCSK9 inhibition,atherosclerotic plaque,magnetic resonance imaging (MRI),peripheral artery disease (PAD)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要